Search

Your search keyword '"Vanlemmens, L."' showing total 227 results

Search Constraints

Start Over You searched for: Author "Vanlemmens, L." Remove constraint Author: "Vanlemmens, L."
227 results on '"Vanlemmens, L."'

Search Results

1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

6. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

9. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

10. LBA12 eMouvoir: Randomised phase III trial evaluating the impact of a personalized and remote physical activity (PA) for breast cancer survivors (BCS). Results on the quality of life (QoL)

12. L’engagement en matière de préservation de la qualité de vie des patients atteints de cancer : l’exemple des RCSF — Rencontres annuelles cancer sexualité et fertilité.

17. 125P Cognitive impairment in breast cancer patients up to 18 months after cancer treatments: The French multicentric longitudinal CANTO-Cog cohort substudy

18. 1694P Coffee and tea consumption (CTC), patient-reported (PRO), and clinical outcomes in a longitudinal study of patients (pts) with breast cancer (BC)

19. 314P Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane

22. 151P Impact of germline BRCA (gBRCA) mutation (m) status on clinical characteristics and patterns of care among women with early breast cancer (eBC): An analysis of the observational prospective CANTO cohort

24. 1817MO Long-term patient reported outcomes (PRO) and hematologic toxicity among patients (pts) who received granulocyte-colony stimulating factors (G-CSF) during chemotherapy (CT) for early breast cancer (EBC)

25. 1710P International multicentric evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits (TV) during the COVID-19 outbreak

26. 183O Use of physical activity (PA) and supportive care (SC) among patients (pts) with early breast cancer (BC) reporting cancer-related fatigue (CRF)

27. Baseline quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): The French multicentric prospective CANTO cohort study

28. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

29. Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

30. Abstract P1-15-03: Association between exercise, pathological complete response, and treatment tolerability in patients receiving neoadjuvant chemotherapy for operable breast cancer: Results from the CANTO study

31. Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort

32. PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)

34. Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC)

35. Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC)

36. Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program

37. Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses

38. Abstract P5-20-03: Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcome in 2863 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)- Results from the French ESME UNICANCER program

39. Abstract P6-12-18: CANTOCHEM: Analysis of chemotherapy practice and early side effects in the 6090 first patients from the prospective CANTO cohort

40. Abstract PD7-06: MAAT: Menses after adjuvant treatment. Prediction of menses recovery after chemotherapy for early breast cancer (BC) by using a nomogram model in UNICANCER PACS04 and PACS05 trials

41. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study

42. FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis

45. Concerns of young women with breast cancer and theirs partners from chemotherapy to follow-up: a cross-sectional study

Catalog

Books, media, physical & digital resources